Assay News and Research

RSS

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

The lack of new or repurposed drugs to treat patients with severe or critical COVID-19 has been one of the biggest hurdles to reducing mortality rates in the ongoing pandemic caused by SARS-CoV-2. A new study describes the potential for the use of the plant molecule isorhamnetin in the management of this virus.

19 Apr 2021

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.

19 Apr 2021

Obesity, hypertension and smoking linked to lower vaccine-induced antibody production against SARS-CoV-2

In a recent study posted to the medRxiv preprint server, a research group from Italy has demonstrated that the antibody response can be blunted in subjects with certain risk factors shortly after the second dose of mRNA vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Apr 2021

Numerous agents with anti-SARS-CoV-2 potential discovered with crystallographic screening

An international team of researchers focused on the macrodomain part of the non-structural protein 3 (Nsp3) gene product that SARS-CoV-2 uses to overturn the host cell’s natural antiviral response. The team provided a template that can help develop novel antivirals that are direct-acting and can combat the current pandemic.

16 Apr 2021

Single dose of Oxford–AstraZeneca COVID vaccine shown to be more immunogenic than natural infection

By investigating antibody and T cell responses to a single dose of the Oxford–AstraZeneca COVID-19 vaccine, researchers from Sri Lanka and the United Kingdom have found that more than 90% of vaccinated individuals produced an adequate amount of antibodies after receiving only one dose of the vaccine – irrespective of their age and gender.

16 Apr 2021

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Researchers in the United States have demonstrated the efficacy of the vaccine INO-4800 against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Apr 2021

Biognosys announces strategic agreement with Siemens Healthineers

Biognosys announces today that it has established a strategic agreement with Siemens Healthineers through its clinical laboratory in Berkeley, California.

From Biognosys 14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Researchers use a photostabilizer to modulate fluorescence blinking in biochemical assays

Fluorescence spectroscopy is indispensable in biomedical diagnostics. One can think of turning on fluorescence as turning on a flashlight in a dark room.

13 Apr 2021

Novel ultrasensitive assay to measure cathepsin B in the blood

Scientists at the Walter Reed Army Institute for Research demonstrated the potential of a novel blood test for cathepsin B, a well-studied protein important to brain development and function, as an indicator for a range of disease states.

13 Apr 2021

Researchers identify SARS-CoV-2 antiviral compounds using protein assay

During the process of SARS-CoV-2 infection, once the virus penetrates the host cell, two open reading frames, ORF1a and ORF1ab, are translated. ORF1ab is responsible for the production of 16 nonstructural proteins (nsp). Several viral proteases such as 3CLpro and PLpro (papain-like protease) produce 1-16 nsps. A new study has been published in bioRxiv* preprint server, which deals with identifying drugs that are effective as PLpro inhibitors.

13 Apr 2021

SARS-CoV-2 viable 21 days in blood, mucus, semen, urine, but just 24 hours in breast milk

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), spreads through respiratory droplets and aerosols expelled when infected individuals cough, sneeze, breathe or sing.

13 Apr 2021

Inhibition of nsp14 methyltransferase as a potential antiviral target for SARS-CoV-2

Beyond vaccination, the broad-spectrum antiviral medication remdesivir has robust clinical evidence and is known as the best antiviral treatment to reduce severe COVID-19 infection in hospitalized patients. Research led by John F.X. Diffley of the Chromosome Replication Laboratory suggests a potential therapeutic target for treatment development is the viral RNA cap methyltransferases, essential for viral protein translation and immune evasion.

13 Apr 2021

Children less likely to spread SARS-CoV-2 than adults

A study conducted by researchers in Canada suggests that children may be less likely than adults to spread the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

12 Apr 2021

New test offers a simpler way to quantify the reservoir of intact viruses in HIV patients

A new test that measures the quantity and quality of inactive HIV viruses in the genes of people living with HIV may eventually give researchers a better idea of what drugs work best at curing the disease.

12 Apr 2021

Small molecule inhibitors of SARS-CoV-2 identified by screening

A new study describes the identification of small molecule inhibitors that block the catalytic activity of the crucial viral non-structural protein 5 (nsp5), using a large-scale screening method.

12 Apr 2021

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Researchers at the Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, USA, showed that the SARS-CoV-2 spike E484K mutation reduces antibody neutralization.

12 Apr 2021

Screening for SARS-CoV-2 non-structural protein 14 inhibitors

In a paper recently uploaded to the preprint server bioRxiv* by Diffley et al. (April 8th, 2021), inhibitors of one essential SARS-CoV-2 non-structural protein are explored, with four compounds, in particular, identified as potential antiviral leads that exhibit synergistic effects with antiviral drug remdesivir.

12 Apr 2021

Previously approved drugs starting points for COVID-19 therapeutics

Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19).

11 Apr 2021

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers in London, UK, have identified several compounds with SARS-CoV-2 inhibiting properties, that potentially may be developed into antiviral solutions in the future.

9 Apr 2021

Assay News and Research

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

Obesity, hypertension and smoking linked to lower vaccine-induced antibody production against SARS-CoV-2

Numerous agents with anti-SARS-CoV-2 potential discovered with crystallographic screening

Single dose of Oxford–AstraZeneca COVID vaccine shown to be more immunogenic than natural infection

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Biognosys announces strategic agreement with Siemens Healthineers

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Researchers use a photostabilizer to modulate fluorescence blinking in biochemical assays

Novel ultrasensitive assay to measure cathepsin B in the blood

Researchers identify SARS-CoV-2 antiviral compounds using protein assay

SARS-CoV-2 viable 21 days in blood, mucus, semen, urine, but just 24 hours in breast milk

Inhibition of nsp14 methyltransferase as a potential antiviral target for SARS-CoV-2

Children less likely to spread SARS-CoV-2 than adults

New test offers a simpler way to quantify the reservoir of intact viruses in HIV patients

Small molecule inhibitors of SARS-CoV-2 identified by screening

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Screening for SARS-CoV-2 non-structural protein 14 inhibitors

Previously approved drugs starting points for COVID-19 therapeutics

Researchers identify several novel SARS-CoV-2 inhibitors

Pioneering Live Cell Imaging - Yokogawa's Impact and Innovations

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Latest News